Article
A genomic-led strategy to anticipate drug safety effects.
PLoS genetics - 1 Jul 2026
Ferolito Brian R, Horimoto Andrea R V R, Gravel-Pucillo Kai, Golden Daniel J, Dashti Hesam, Giambartolomei Claudia, Rasooly Danielle, Matty Rachael, Gaziano Liam, Tsepilov Yakov, Costa Lauren, Kosik Nicole, Ioannidis Harris, Karim Mohd, Winicki Giovanna, Hunter Fiona, Langenberg Claudia, Whittaker John C, Cai Tianxi, Peloso Gina M, Zdrazil Barbara, Ghoussaini Maya, Leach Andrew R, Muralidhar Sumitra, Smit Ines A, Casas Juan P, Gaziano J Michael, Cho Kelly, Pereira Alexandre C
Abstract excerpt
Safety-related issues account for approximately 25% of failures in new drug discovery programs. On top of that, many are discovered during post-marketing surveillance, significantly limiting drug utility and application. To proactively address these concerns, we developed a genetics-led strategy leveraging Mendelian Randomization (MR) across large-scale genetic datasets from the Million Veteran Program, FinnGen,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.